Fotivda
Chemical Name | tivozanib |
Dosage Form | Capsule (oral; 0.89 mg, 1.34 mg) |
Drug Class | Kinase inhibitors |
System | Urinary |
Company | AVEO Pharmaceuticals |
Approval Year | 2021 |
Indication
- Indicated for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies